Bambusa Therapeutics Initiates Phase Ib Trial of BBT002 Bispecific Antibody for COPD Treatment
核心洞察
Bambusa Therapeutics (搜索) has dosed the first patient in a Phase Ib clinical trial of BBT002, a novel bispecific antibody targeting IL-4Rα (搜索) and IL-5 (搜索) for chronic obstructive pulmonary disease treatment.
BBT002 is designed to simultaneously inhibit IL-4 (搜索)/IL-13 (搜索) and IL-5 (搜索) signaling pathways, potentially offering broader and more durable suppression of type 2 inflammation than existing single-target therapies.
The Phase Ib study will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of BBT002 in COPD and other type 2 inflammatory respiratory conditions, with initial data expected in the second half of 2026.
Bambusa Therapeutics (搜索) has announced the dosing of the first patient in a Phase Ib clinical trial of BBT002, a novel bispecific antibody targeting chronic obstructive pulmonary disease (COPD). The clinical-stage biotechnology company is pioneering next-generation bispecific antibodies for immunology and inflammation, with BBT002 representing a platform-in-a-molecule approach targeting IL-4Rα (搜索) and IL-5 (搜索).
Novel Dual-Target Approach for Type 2 Inflammation
BBT002 is designed to simultaneously inhibit IL-4 (搜索)/IL-13 (搜索) and IL-5 (搜索) signaling, two central and complementary drivers of type 2 inflammation that shape disease expression across multiple organ systems and stages of life. This dual-targeting strategy addresses a fundamental limitation in current therapeutic approaches, which largely treat individual disease manifestations in isolation, often leaving patients with incomplete or transient control as their disease evolves.
Type 2 inflammation underlies a continuum of allergic and inflammatory disorders that evolve across the human lifespan, ranging from atopic dermatitis and food allergy in early childhood, to asthma and chronic rhinosinusitis with nasal polyps in adulthood, and ultimately to COPD in later life. By targeting both pathways in a single, long-acting molecule, BBT002 has the potential to deliver broader and more durable suppression of underlying disease biology than existing single-target therapies.
Clinical Trial Design and Timeline
The Phase Ib study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BBT002 in COPD as well as other type 2 inflammatory respiratory indications, including asthma and chronic rhinosinusitis with nasal polyps. Initial data are anticipated in the second half of 2026.
"COPD has seen remarkably limited therapeutic innovation over the past several decades," said Dr. Shanshan Xu, Founder and Chief Executive Officer of Bambusa Therapeutics (搜索). "Moving BBT002 from healthy volunteers to proof-of-concept studies in just seven months demonstrates the power of our bispecific platform and our ability to execute with urgency while maintaining the scientific rigor required to advance meaningful new options for patients."
Expanding Clinical Pipeline
The advancement of BBT002 represents part of Bambusa's broader clinical development strategy. Dr. Xu noted that "2025 was a year that demonstrated Bambusa's execution-first culture," with the company entering 2026 positioned to deliver up to 10 clinical readouts, including five proof-of-concept studies, as they continue to advance new possibilities for patients with type 2 inflammatory diseases.
Platform Technology and Pipeline
Bambusa Therapeutics (搜索) is developing a portfolio designed to transform care across a wide spectrum of chronic diseases, powered by an innovative antibody engineering platform featuring half-life extension and high-concentration subcutaneous delivery. The company's pipeline includes multiple bispecific antibodies at various stages of development:
BBT001 is a first-in-class half-life-extended bispecific antibody targeting IL-4Rα (搜索) and IL-31 (搜索) currently in Phase Ib proof-of-concept development for atopic dermatitis and other type 2 inflammatory skin diseases. BBT002 is being developed for type 2 inflammatory disorders including COPD, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and food allergy. Additionally, BBT003 (搜索) and BBT004 (搜索) are preclinical programs focused on gastroenterology and rheumatology, respectively.